FI20115005A - Melanoma antigen - Google Patents

Melanoma antigen Download PDF

Info

Publication number
FI20115005A
FI20115005A FI20115005A FI20115005A FI20115005A FI 20115005 A FI20115005 A FI 20115005A FI 20115005 A FI20115005 A FI 20115005A FI 20115005 A FI20115005 A FI 20115005A FI 20115005 A FI20115005 A FI 20115005A
Authority
FI
Finland
Prior art keywords
melanoma antigen
melanoma
antigen
Prior art date
Application number
FI20115005A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI123050B (en
Inventor
Yutaka Kawakami
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22869773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20115005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US1995/005063 external-priority patent/WO1995029193A2/en
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of FI20115005A publication Critical patent/FI20115005A/en
Application granted granted Critical
Publication of FI123050B publication Critical patent/FI123050B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
FI20115005A 1994-04-22 2011-01-04 Melanoma antigens FI123050B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/231,565 US5874560A (en) 1994-04-22 1994-04-22 Melanoma antigens and their use in diagnostic and therapeutic methods
US23156594 1994-04-22
US08/417,174 US5844075A (en) 1994-04-22 1995-04-05 Melanoma antigens and their use in diagnostic and therapeutic methods
US41717495 1995-04-05
US9505063 1995-04-21
PCT/US1995/005063 WO1995029193A2 (en) 1994-04-22 1995-04-21 Melanoma antigens

Publications (2)

Publication Number Publication Date
FI20115005A true FI20115005A (en) 2011-01-04
FI123050B FI123050B (en) 2012-10-15

Family

ID=22869773

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115005A FI123050B (en) 1994-04-22 2011-01-04 Melanoma antigens

Country Status (5)

Country Link
US (6) US5874560A (en)
EP (1) EP2311952A3 (en)
JP (1) JP2010178739A (en)
CA (1) CA2722364C (en)
FI (1) FI123050B (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
ES2224113T5 (en) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services ANTIGEN POLYPEPTIDE ASSOCIATED WITH MELANOMA, EPITHOPOS OF THE SAME AND VACCINES AGAINST MELANOMA.
US6660276B1 (en) 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
CA2243235C (en) * 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US7015312B1 (en) * 1996-02-09 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US20020155093A1 (en) * 1997-02-18 2002-10-24 Houghton Alan N. Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US6025470A (en) * 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
CN1313481C (en) * 1997-06-23 2007-05-02 路德维格癌症研究所 Isolated nona- and decapeptides which bind to HLA molecules,and the use thereof
US6872518B2 (en) * 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US6395876B1 (en) * 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
WO1999046988A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions and methods for antigen-specific vaccination
US6465180B1 (en) * 1999-03-17 2002-10-15 The Regents Of The University Of California Detection of premalignant melanocytes
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
CA2382774A1 (en) * 1999-05-25 2000-11-30 Human Genome Sciences, Inc. Meth1 and meth2 polynucleotides and polypeptides
AU7917200A (en) * 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001070767A2 (en) * 2000-03-20 2001-09-27 Genzyme Corporation Therapeutic anti-melanoma compounds
FR2806727A1 (en) * 2000-03-23 2001-09-28 Pf Medicament MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING IN THE N-TERMINAL END A GLUTAMIC ACID OR GLUTAMINE IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALT
US20030194696A1 (en) * 2000-03-28 2003-10-16 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
US7067251B2 (en) * 2000-03-28 2006-06-27 University Of Rochester Methods of directly selecting cells expressing inserts of interest
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
ATE474931T1 (en) * 2000-04-28 2010-08-15 Mannkind Corp EPITOPE SYNCHRONIZATION IN ANTIGEN-PRESENTING CELLS
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
JP2004502411A (en) * 2000-05-31 2004-01-29 ジェンザイム・コーポレーション Therapeutic anti-melanoma compounds
CA2416890A1 (en) * 2000-08-04 2002-02-14 Genzyme Corporation Therapeutic anti-melanoma compounds
US20020177547A1 (en) * 2001-01-16 2002-11-28 Karin Molling Pharmaceutical compositions for treating or preventing cancer
EP1222928A3 (en) * 2001-01-16 2003-11-05 Universität Zürich Institut für Medizinische Virologie Pharmaceutical compositions for treating or preventing cancer, especially melanoma
JP2005503118A (en) * 2001-02-14 2005-02-03 ジェンザイム・コーポレーション Modified peptide ligand
HUP0402656A3 (en) 2001-02-20 2012-03-28 Ortho Mcneil Pharm Inc A cell therapy method for the treatment of tumors
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
KR100669065B1 (en) * 2001-04-03 2007-01-15 다카라 바이오 가부시키가이샤 Cytotoxic t lymphocyte
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
US20040202654A1 (en) * 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
MXPA03010507A (en) * 2001-05-15 2005-07-25 Johnson & Johnson Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease.
US20080220015A1 (en) * 2001-08-03 2008-09-11 Nokad, S.A. Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US7419957B2 (en) * 2001-08-22 2008-09-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
EP2314712B1 (en) * 2001-11-07 2014-01-08 Mannkind Corporation Expression vectors encoding epitopes of antigens and methods for their design
US6783944B2 (en) 2002-01-04 2004-08-31 The Regents Of The University Of California Genetic changes in atypical nodular proliferations in congenital melanocytic nevi
DE10229872A1 (en) * 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
US20040018622A1 (en) * 2002-07-17 2004-01-29 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of skin disorders
EP1556082A1 (en) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ZA200507562B (en) * 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
CA2529058A1 (en) 2003-06-11 2005-01-13 The University Of Chicago Increased t-cell tumor infiltration by mutant light
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
CA2529056C (en) * 2003-06-17 2013-09-10 Mannkind Corporation Combinations of tumor-associated antigens in compositions for various types of cancers
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
US20080038838A1 (en) * 2003-10-10 2008-02-14 Towa Kagaku Co., Ltd. Dioxin-Binding Material and Method of Detecting or Quantifying Dioxin
EP1684076B1 (en) * 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
WO2006037059A2 (en) 2004-09-27 2006-04-06 The Johns Hopkins Universtiy Point-of-care mass spectrometer system
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
US20100080792A1 (en) * 2005-06-16 2010-04-01 Dorothee Herlyn Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
WO2006138568A2 (en) * 2005-06-17 2006-12-28 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
JP2008543314A (en) * 2005-06-17 2008-12-04 マンカインド コーポレイション Epitope analog
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20070178113A1 (en) * 2005-11-22 2007-08-02 Backstrom B T Superantigen conjugate
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
DE102006035618A1 (en) * 2006-07-31 2008-02-07 Curevac Gmbh New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
EP2084267B1 (en) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) * 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
US20090093429A1 (en) * 2007-02-08 2009-04-09 Yang-Xin Fu Combination therapy for treating cancer
ES2433967T3 (en) 2007-05-14 2013-12-13 The University Of Chicago Antibody-LIGHT fusion products as cancer therapeutic products
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
ES2588705T3 (en) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Use of liposomes in a vehicle comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
CA2710534C (en) 2008-01-31 2018-09-04 Curevac Gmbh Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
ES2524699T3 (en) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a vehicle comprising a continuous phase of a hydrophobic substance
ES2565779T3 (en) * 2008-09-02 2016-04-06 Cedars-Sinai Medical Center CD133 epitopes
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
DK2427485T3 (en) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd CD133 epitopes
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
EP2548025A4 (en) 2010-03-17 2013-09-25 Univ Michigan Using phage epitopes to profile the immune response
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP2449113B8 (en) 2010-07-30 2015-11-25 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
CN105288602A (en) * 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 Antigen presenting cancer vaccine
CA2858876A1 (en) 2011-12-15 2013-06-20 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2869828B1 (en) 2012-07-09 2018-01-03 The Regents of The University of California Vault immunotherapy
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2014152795A2 (en) 2013-03-14 2014-09-25 Schentag Jerome J Cholestosome vesicles for incorporation of molecules into chylomicrons
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
JP6896421B2 (en) 2013-08-21 2021-06-30 キュアバック アーゲー Respiratory syncytial virus (RSV) vaccine
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
AU2017315321A1 (en) * 2016-08-23 2019-04-11 Mary P. Mccourt Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells
KR20190123328A (en) * 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cancer vaccine
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5990052A (en) * 1982-11-16 1984-05-24 Katsu Taniguchi Melanoma diagnosis medicine using monoclonal specific antibody
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5679511A (en) * 1986-10-06 1997-10-21 Donald Guthrie Foundation For Medical Research, Inc. CDNA clones for a regulatory protein in the melanin-production pathway
EP0440663A1 (en) 1988-08-08 1991-08-14 IFFIU, Michael A. Collapsible recumbent bicycle with streamlined three-part folding canopy
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1992021767A1 (en) * 1991-06-05 1992-12-10 Bristol-Myers Squibb Company Me20: monoclonal antibodies and antigen for human melanoma
JPH07503134A (en) * 1992-01-21 1995-04-06 ラドウィック　インスティテュート　フォア　キャンサー　リサーチ Method for measuring cytotoxic T cell precursors
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
WO1993020185A1 (en) 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US6001975A (en) 1993-03-18 1999-12-14 Ludwig Institute For Cancer Research Precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
WO1994023067A1 (en) * 1993-03-31 1994-10-13 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
ES2224113T5 (en) 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services ANTIGEN POLYPEPTIDE ASSOCIATED WITH MELANOMA, EPITHOPOS OF THE SAME AND VACCINES AGAINST MELANOMA.
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
EP0756604A1 (en) 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5837476A (en) 1995-03-03 1998-11-17 Ludwig Institute Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma

Also Published As

Publication number Publication date
US5844075A (en) 1998-12-01
EP2311952A2 (en) 2011-04-20
US20110287043A1 (en) 2011-11-24
US8273724B2 (en) 2012-09-25
FI123050B (en) 2012-10-15
JP2010178739A (en) 2010-08-19
CA2722364A1 (en) 1995-11-02
CA2722364C (en) 2013-12-31
US7803614B2 (en) 2010-09-28
US5874560A (en) 1999-02-23
US20080233637A1 (en) 2008-09-25
US20110027299A1 (en) 2011-02-03
US8030280B2 (en) 2011-10-04
EP2311952A3 (en) 2011-06-01
US5994523A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
FI20115005A (en) Melanoma antigen
FI964235A (en) Melanoma antigen
ATA166795A (en) BIS-RESORCINYLTRIAZINE
ATA147195A (en) ALKOXYPHENYL-SUBSTITUTED BISBENZOYLPHOSPHINOXIDE
DE69513415D1 (en) IMPROVED TIMES
ATA11894A (en) STAUFÖRDERBAHN
KR960000238U (en) Carrying case
KR960003039U (en) Improved Pharmaroy
FI1474U1 (en) Staellning Foer tobaksprodukter
FI1360U1 (en) Justerbar details
KR960002814U (en) Problem
BR9402348A (en) Improved Passaguá
ITRE940049A0 (en) XX
ATE197372T1 (en) PRE-DOUGH
ES1029347Y (en) MOTO-PUMP
FI1578U1 (en) Floete
FI1539U1 (en) Sadelstaellning
DE9408017U1 (en) case
BR9404091A (en) Muchileiro
BR9401864A (en) Neck-swivel
BR9405342A (en) Auto-lift
FI940746A0 (en) Foer hushaollsbruk avsett kaerl Foer biologiskt avfall
BR9403990A (en) Quandriciclo cycle-car
BR9403759A (en) Mastercalc
BR9403758A (en) Multiplic

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 123050

Country of ref document: FI

Kind code of ref document: B

MA Patent expired